Toronto, Ontario--(Newsfile Corp. - September 3, 2020) -
Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has filed five patent applications with the United States Patent and Trademark Office (USPTO) pertaining to new treatments combining healing compounds in medical cannabis with healing compounds from mushrooms (edible and psychedelic), and other natural plants known for their medicinal properties. These patent applications have formulation claims directed to methods of treating numerous conditions including cancer, psychiatric disorders, addiction (opioid and alcohol), viral diseases, obesity, and inflammatory disorders. These first five patents are just the beginning of what the Company expects to be a full portfolio of intellectual property including blocking patents designed to protect Aion Therapeutic's discoveries.
The backbone of the Company's combinatorial treatment formulation discovery platform is artificial intelligence (AI) techniques. Using AI, the Company intends to create a full line of therapeutic products that includes combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals, as well as, individualized treatments for personalized medicine using human genome and other data unique to an individual.
- Findings suggest combinations of medical cannabis-based compounds and medical mushroom-derived compounds can be used to treat diseases including cancer, psychiatric diseases (including depression, PTSD, and anxiety), addiction (opioid and alcohol), viral diseases, obesity, and inflammatory disorders.
- Patent applications filed to protect these findings will be a significant addition to Aion Therapeutic's global intellectual property portfolio.
The titles of these five patent applications are:
- Compositions and Methods for Treatment of Cancers;
- Compositions and Methods for Treatment of Psychoses and Psychotic Disorders;
- Antiviral Compositions and Methods for Their Use;
- Compositions and Methods for Treatment of Inflammation; and
- Compositions and Methods for Promoting Weight Loss and For Treatment of Obesity.
"With these filings, we have initiated the process to formally protect and secure our intellectual property developments combining our in-depth knowledge of the healing compounds in medical cannabis and medical mushrooms with our expertise in the use of Artificial Intelligence (AI) techniques to develop combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals," stated Aion Therapeutic's Executive Chairman and inventor of these patents, Dr. Stephen Barnhill. "Natural products derived from plants have played a leading role in cancer drug discovery, which is demonstrated by the large number of approved anti-cancer agents derived from these sources. Such drugs include effective chemotherapeutic agents such as doxorubicin, irinotecan, topotecan, paclitaxel, docetaxel, and vincristine. Fungi-derived natural products have also been an excellent source of pharmaceuticals as well, including cyclosporine and certain types of statins. We firmly believe that combining compounds from cannabis and mushrooms (medical and edible) will create an entirely new class of successful therapeutic treatments."
Mr. Graham Simmonds, Executive Vice Chair and CEO of Aion Therapeutic stated, "We would like to congratulate our team on these new discoveries and associated patent filings. This exciting announcement brings to life precisely what Aion Therapeutic hoped to achieve in its recent acquisition of PCAI Pharma. I fully expect that these remarkable developments are the first of a series of product developments and the intellectual property protection we look forward to continue seeing from our team."
Dr. Barnhill added, "Jamaica provides Aion Therapeutic an incredibly unique opportunity in that it is one of the very few countries in the world where mushrooms (both edible and psychedelic) have never been made illegal and are openly sold. In addition, medical cannabis is legal via Cannabis License Authority (CLA) approved licenses. It is worth noting that Aion Therapeutic has this incredible research and development opportunity through our partnership with Apollon Formularies Jamaica, Ltd., a CLA licensed medical cannabis company. This partnership allows Aion Therapeutic to legally discover these unique medical cannabis and medical mushroom combinations for therapeutic product formulations. We believe that we can build a large portfolio of blocking patents while most of the rest of the world faces legal hurdles that limit efforts in this type of research and discovery."
Aion Therapeutic's intellectual property counsel, Pinnacle IP Strategies LLC ("Pinnacle"), drafted and will prosecute the patent applications. According to Pinnacle, Aion Therapeutic's provisional patent filings in the U.S. will provide Aion Therapeutic a right of priority under the Paris Convention to pursue patent protection to Jamaica, as well as, priority for over 170 countries under the Patent Cooperation Treaty ("PCT"). Establishing an effective filing date for Aion Therapeutic's inventions in the U.S. preserves that priority date - with up to one year to pursue a subsequent filing in any country that is a party to those agreements.
About Aion Therapeutic Inc.
Aion Therapeutic Inc. (formerly, Osoyoos Cannabis Inc.) has a joint-venture agreement with a private, vertically-integrated licensed producer under the Cannabis Act (Canada) to offer contract tolling extraction services to third-party businesses. Additionally, the Company recently acquired 1196691 B.C. Ltd. d/b/a "PCAI Pharma" (www.pcai.ca) and its wholly-owned subsidiary AI Pharmaceuticals Jamaica Limited, a private corporation incorporated and operating under the laws of Jamaica. The business of AI Pharma involves, research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, the Company is creating a strong international intellectual property portfolio related to their discoveries.
For further information, please contact:
Investor Relations & Financial Media
Integrity Media Inc.
team@integritymedia.com
Toll Free: (888) 216-3595
www.IntegrityMedia.com
Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO
(416) 843-2881
DISCLAIMER & READER ADVISORY
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "may", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals; licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
